NCT02425098View on ClinicalTrials.gov

Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore

PHASE2CompletedINTERVENTIONAL
Enrollment

351

Participants

Timeline

Start Date

June 3, 2015

Primary Completion Date

September 18, 2017

Study Completion Date

September 18, 2017

Conditions
Dengue Fever
Interventions
BIOLOGICAL

Takeda's Tetravalent Dengue Vaccine Candidate (TDV)

TDV subcutaneous injection

BIOLOGICAL

Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)

High-dose TDV subcutaneous injection

Trial Locations (3)

169608

Singapore General Hospital, Singapore

308433

Tan Tock Seng Hospital, Singapore

529889

Changi General Hospital, Singapore

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY